Printer Friendly

Fuisz Technologies Ltd. and Bayer Corporation Sign Development Agreement

CHANTILLY, Va., Nov. 25 /PRNewswire/ -- Fuisz Technologies Ltd. (Nasdaq-NNM: FUSE) announced today that it has entered into an agreement with Bayer Corporation's Consumer Care Division, based in Morris Township, N.J., to enable the development of an over-the-counter (OTC) drug formulation using one of Fuisz's proprietary rapid dissolve dose forms.

"This agreement demonstrates the ongoing interest among leading, global pharmaceutical companies for the varied applications of our proprietary rapid dissolve technologies," said Richard C. Fuisz, M.D., Chairman and Chief Executive Officer of Fuisz.

Fuisz Technologies Ltd. is engaged in the development and commercialization of a wide range of drug delivery and food applications.
 To receive additional information on Fuisz Technologies, Ltd.,
 via fax at no charge,
 dial 1-800-PRO-INFO and enter code 203 or ticker symbol FUSE


SOURCE Fuisz Technologies Ltd.
 -0- 11/25/96


/CONTACT: Richard C. Fuisz, M.D., Chairman and CEO of Fuisz, 703-803-3260; or Doug DeLieto -- general, Judith Sylk-Siegel -- media, or Brian Gill -- analysts, of Financial Relations Board, 212-661-8030/

(FUSE)

CO: Fuisz Technologies Ltd.; Bayer Corporation ST: Virginia, New Jersey IN: MTC FOD SU:

MP -- NYM049 -- 3501 11/25/96 08:58 EST http://www.prnewswire.com
COPYRIGHT 1996 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 25, 1996
Words:191
Previous Article:Sterling Software Delivers Web-Based Interface For IBM's Electronic Mail and Calendar System
Next Article:Bankers Trust Selects Object Design's ObjectStore for Global Risk Management Trading System
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters